Inactive Instrument

News Provectus Pharmaceuticals, Inc. OTC Bulletin Board

Stocks

PVCT

US74373F1003

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

08-13	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-07	Provectus Biopharmaceuticals, Inc. Highlights Peer-Reviewed Study Demonstrating Opposing Mechanistic Effects Of Rose Bengal Sodium At The Same Dose	CI

All News

Mentions Relevance

08-13	Provectus: Q2 Earnings Snapshot	AQ
08-13	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-22	VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase	AQ
07-07	Provectus Biopharmaceuticals, Inc. Highlights Peer-Reviewed Study Demonstrating Opposing Mechanistic Effects Of Rose Bengal Sodium At The Same Dose	CI
07-07	Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose	AQ
06-30	Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections	AQ
06-25	Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)	AQ
06-25	Provectus Biopharmaceuticals, Inc. Launches Veripure Open Science Program For Medical Research Access To PV-10	CI
06-18	Provectus Biopharmaceuticals, Inc. - Shareholder/Analyst Call
06-08	Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders	AQ
05-18	Provectus Biopharmaceuticals reports oral pv-10 anti-tumor activity in preclinical bladder cancer study	RE
05-18	Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End	AQ
05-18	Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study	CI
05-14	Provectus: Q1 Earnings Snapshot	AQ
05-14	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-04	Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis	AQ
05-04	Provectus Biopharmaceuticals, Inc. Presents New Data on Rose Bengal Photodynamic Antimicrobial Therapy At Arvo 2026	CI
04-20	Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee	AQ
04-02	Provectus Biopharmaceuticals Highlights Preclinical Evidence Of PV-10-Mediated Immune Modulation In Burn Wound Healing	CI
04-02	Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment	AQ
03-26	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-26	Provectus: Q4 Earnings Snapshot	AQ
03-25	Provectus Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-13	Provectus: Q3 Earnings Snapshot	AQ
11-13	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI